Histological and Biochemical Impact of Pravastatin in Patients with NAFLD.
Histological and Biochemical Impact of Pravastatin in Patients with NAFLD (CKA001)
The UVA Digestive Health Center of Excellence is seeking men and women ages 18 to 90 with Nonalcoholic fatty liver disease (NAFLD) to participate in a clinical trial using the investigational medication pravastatin. Pravastatin is a cholesterol-lowering medicine commonly used to treat high cholesterol, but is currently not approved for the treatment of NAFLD. The purpose of the study is to see if pravastatin is effective in positively impacting fatty liver disease along with treating hyperlipidemia a common problem shared by many patients with NAFLD. Patients that enroll in the study will be randomized to receive pravastatin two 40 mg capsules daily vs. placebo for 24 months. Physical & laboratory assessments will occur once every 3 months for two years duration; at the end of the 2 years, you will undergo a liver biopsy to assess for any changes. During the baseline evaluation and during the end of study visit, patients will have their body composition measured thru BodPod & bicycle exercise testing to measure their physical conditioning. Eligible patients will have all study-related care and the study medication provided free of charge; no compensation for time and travel will be provided. Contact: Sandra Oliphant, RN (434) 982-0871 IRB/HIC 14452 GCRC CKA001
Gastroenterology & Hepatology (Digestive Health)